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Summary In recent years, nanoparticles (NPs) have increasingly found practical applications
in technology, research and medicine. The small particle size coupled to their unique chemical
and physical properties is thought to underlie their exploitable biomedical activities. Here, we
review current toxicity studies of NPs with clinical potential. Mechanisms of cytotoxicity are
discussed and the problem of extrapolating knowledge gained from cell-based studies into a
human scenario is highlighted. The so-called ‘proof-of-principle’ approach, whereby ultra-high
NP concentrations are used to ensure cytotoxicity, is evaluated on the basis of two consider-
ations; ﬁrstly, from a scientiﬁc perspective, the concentrations used are in no way related to
the actual doses required which, in many instances, discourages further vital investigations.
Secondly, these inaccurate results cast doubt on the science of nanomedicine and thus, quite
dangerously, encourage unnecessary alarm in the public. In this context, the discrepancies
between in vitro and in vivo results are described along with the need for a unifying protocol
for reliable and realistic toxicity reports.
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ntroduction
anoparticles have a large surface area to volume ratio
hich leads to an alteration in biological activity compared
o the parent bulk materials. In the past two decades,
he use of nanoparticles (NPs) in experimental and clinical
ettings has risen exponentially due to their wide range
f biomedical applications, for example in drug delivery,
maging and cell tracking [1—4]. This highlights the need to
onsider not only the usefulness of NPs but also the poten-
ially unpredictable and adverse consequences of human
xposure thereto. In this context, NP toxicity refers to
he ability of the particles to adversely affect the nor-
al physiology as well as to directly interrupt the normal
tructure of organs and tissues of humans and animals. It
s widely accepted that toxicity depends on physiochemi-
al parameters such as particle size, shape, surface charge
nd chemistry, composition, and subsequent NPs stability.
he exact underlying mechanism is as yet unknown, how-
ver, recent literature suggests cytotoxicity to be related
o oxidative stress and pro-inﬂammatory gene activation
5—7]. Further to particle-related factors, the administered
ose, route of administration and extent of tissue dis-
ribution seem important parameters in nano-cytotoxicity.
ypically, cell-based toxicity studies use increasing doses of
he NP in order to observe dose-related cellular or tissu-
ar toxicity. Such dose—response correlations are the basis
or determining safe limits of particle concentrations for
n vivo administration. Despite the theoretically brilliant
ogic, animal and human studies have taught us differently
nd highlighted the issue of the feasibility of correlating
rgan toxicity with the pre-determined dose; there exists
widely acknowledged problem of extrapolating in vitro
oncentrations into in vivo scenarios which can be subdi-
ided into two points; ﬁrstly, it has yet to be determined
ow efﬁciently any administered NP dose is reaching the tar-
et tissue and secondly, NPs can induce biochemical changes
n vivo which may have gone unnoticed in isolated cell-
ased studies. With the potentially disastrous consequences
n mind, new ways of predicting as yet unpredictable, non-
osage-dependent actions of NPs in vivo must be sought.
part from the dosing issue, another, so far underexposed
rea of nanotoxicity relates to the route of particle adminis-
ration which may also, quite independently from the dose,
nﬂuence toxicity in an adverse fashion. It is sensible to
ssume that biodistribution, accumulation, metabolism and
xcretion of NPs will differ depending on the route of admin-
stration as will its toxicity. So far, no reviews have focused
n the association between different routes of administra-
ion and NP toxicity.
Substances may enter the body via oral ingestion,
nhalation, dermal penetration and intravascular injection
nd subsequently distribute to any organ system. Fig. 1
ummarizes the advantages and disadvantages of each of
he routes. Pulmonary drug delivery shows tremendous
otential but concerns regarding local and systemic toxicity
urrently curb enthusiasm [8]. NP aggregation and subse-
uent tissue inﬂammatory reactions have been postulated
o be the underlying mechanism [9—11]. Topically applicable
ubstances such as sunscreen preparations and cosmetics
lready rely on the use of nano-formulations of titanium-
nd zinc-dioxide by exploiting their ultraviolet radiation
d
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locking ability. In the future, the penetrative capacity of
ertain NPs could be exploited for transdermal drug delivery.
herefore, the mechanistics of transition and potential der-
al or systemic toxicity need to be evaluated. Intravenous
nd oral NP administrations inherently have a more rapid
ystemic effect compared to transdermal administration
nd once within the circulation, most substances are
ubject to ﬁrst-pass metabolism within the liver where they
ay accumulate or distribute via the vasculature to end
rgans including the brain. Despite its innate protection
y the blood—brain-barrier (BBB) against external chemical
nsults, the potential for nanoparticulate matter to perco-
ate through tight junctions renders the brain vulnerable
o potential particle-mediated toxicity. Reliable data on NP
oxicity is therefore necessary to avoid detrimental adverse
ffects.
In this review, we aim to identify clinically relevant
Ps and critically appraise organ-based toxicological studies
hich have been carried out on a cellular and pre-clinical
evel as well as on human volunteers. Furthermore, empha-
is will be placed upon the importance of particle size and
he route of administration with respect to toxicity as the
uthors believe that the latter has not received adequate
valuation despite its fundamental importance with respect
o the clinical setting.
ypes of nanoparticles for clinical applications
Ps have a vast potential in the medical arena as drug
nd gene delivery vehicles, ﬂuorescent labels and contrast
gents [1,12]. For a particle to qualify as a ‘‘true’’ NP, at
east one of its material dimensions must lie within the size
ange of 1—100 nm. The use of NPs as carrier systems for
rugs, particularly chemotherapeutic drugs, is gaining in
opularity due to the ability to speciﬁcally target cancer
ells, enhance efﬁcacy and reduce systemic toxicity. Gold
Ps (AuNP) show several advantageous properties including
non-toxic and biocompatible metal core making them an
deal starting point for nanocarrier systems [13]. Further-
ore, AuNP can undergo multiple surface functionalizations
ombining different moieties such as drugs and targeting
gents which renders them a highly versatile tool for target-
ng [14] (Fig. 3). Other drug nano-vehicles which are already
n clinical use include lipid-based [15], polymer-based [16]
nd biological NPs [17]. Quantum dots (QDs), or semiconduc-
or nanocrystals, are another type of NPs which enjoy a wide
ange of potential clinical applications including cell label-
ng, in vivo imaging and diagnostics [18]. Due to the QD’s
xceptional photophysical properties such as broad absorp-
ion spectra coupled to a narrow emission spectrum, QDs
f different emission colors may be simultaneously excited
y a single wavelength, thus enabling multiplexed detec-
ion of molecular targets [19]. Other ﬂuorescent labels used
n medical research include magnetic NPs such as super-
aramagnetic iron oxide nanoparticles (SPIONs) [20]. SPIONs
re one of the few clinically approved metal oxide NPs and
nd ubiquitous applications in the biomedical ﬁeld such as
agnetic resonance imaging (MRI) [21], drug [22] and gene
elivery [23] and hyperthermic destruction of tumor tissue
22]. Their superparamagnetism confers several advantages:
rstly, the ability to be guided by means of an external
agnetic ﬁeld may be exploited in targeted imaging or
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ing on the mode of administration and sites of deposition,Figure 1 Routes of administration of nanop
drug delivery systems; secondly, the production of cytotoxic
heat when subjected to alternating magnetic ﬁelds could
be utilized in cancer treatments [24]. A different modality
of exposure to metal oxide NPs comprises that of topi-
cally applicable formulations such as creams and sunscreen
lotions containing titanium dioxide and zinc oxide NPs [25].
Here, it is important to determine whether NPs can pen-
etrate deeper into skin layers and possibly be absorbed
into the systemic circulation and accumulate in tissues.
Nanoscaled silver (AgNP) became popular for its marked
antimicrobial effect which is successfully exploited in medi-
cal applications such as silver-impregnated wound dressings,
contraceptive devices, surgical instruments and bone pros-
theses [26—29]. Carbon nanotubes are made from rolled up
sheets of graphene and are classiﬁed as single-walled (SWC-
NTs) or multi-walled carbon nanotubes (MWCNTs) depending
on the constituent numbers of graphene layers. Due to their
unique size and shape, much effort has been dedicated to
analyzing biomedical applications of CNTs. Such extensive
potential requires the meticulous evaluation of toxicity.
This widespread use of different types of NPs in the
biomedical ﬁeld raises concerns over their increasing access
t
c
s
mles and their advantages and disadvantages.
o tissues and organs of the human body and, consequently,
he potential toxic effects. Various studies evaluating
n vitro and in vivo absorption, distribution and biocom-
atibility of NPs have been reviewed and are critically
ppraised in this article. Fig. 2 shows a summary of
iologically important nanoparticles and their possible
outes of administration (adapted from reference [30]).
oxicological proﬁling in cell based targets,
nimal targets and human volunteers
ue to their small size and physical resemblance to physio-
ogical molecules such as proteins, NPs possess the capacity
o revolutionise medical imaging, diagnostics, therapeutics
s well as carry out functional biological processes. But
hese features may underlie their toxicity. Also, depend-oxicity may vary in severity. Therefore, to maintain clini-
al relevance, information on toxicity is presented using a
ystem-based approach focusing on experimental lung, der-
al, liver and brain targets (see Table 1).
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Table 1 Summary of in vitro and in vivo evaluations of nanoparticle toxicity.
Target Nanoparticle Conjugation Concentration
(time/size)/route of
administration
Cellular target Animal target Major outcomes Ref.
Lung PLGA NP Chitosan 300-5000g/mL (4 h) A549 human
lung cancer
cells
Non-toxic even at highest
concentrations.
[31]
Solid lipid NP 500g/mL (24 h) A549 human
lung cancer
cells
No inﬂammatory changes in
lung parenchyma at the critical
concentration of 500g/mL.
Concentrations lower than
200g/mL are thought to be
safe.
[32]
SWCNT 1.56-800g/mL (24 h) A549 human
lung cancer
cells
Low acute cytotoxicity was
further reduced by dispersion
of SWCNTs in serum.
[33]
SWCNT 1 or 5mg/kg (24 h, 1
week, 1 month, 3
months)
Intratracheal
instillation
Sprague-
Dawley
rats
Mortality in 15% of animals
after 24 h exposure to highest
dose due to physical blockage
of airways rather than acute
inﬂammation. Multifocal
granulomatous change on
histology - apparently no
relation to dose or time. No
inﬂammatory change.
[10]
SWCNT 1.5mg/kg (30 days)
Intratracheal
instillation
C57Bl/6 mice Signiﬁcant reduction in
inﬂammatory and ﬁbrotic
changes after exposure of
serum-dispersed particles
relative to the non-dispersed
pendent. Toxicity is
attributable to particle
aggregation rather than
physiochemical property of
individual nanotube.
[9]
SWCNT PEG 47mg on days 0 and 7
(follow-up: 4 months)
Intravenous infusion
Nude mice No signiﬁcant inﬂammatory
changes were observed,
however, particle deposition in
liver macrophages was
observed.
[34]
Toxicologicalconsiderations
of
clinically
applicable
nanoparticles
589
Table 1 (Continued)
Target Nanoparticle Conjugation Concentration
(time/size)/route of
administration
Cellular target Animal target Major outcomes Ref.
MWCNT 0.5, 2 or 5mg/animal
(3 and 15 days)
Intratracheal
instillation
Sprague-
Dawley
rats
Dose-dependent increase in
inﬂammatory markers
post-BAL. Dose-dependent
ﬁbrotic change and interstitial
granuloma formation.
[11]
MWCNT 0.2, 0.5 or 2.7mg/kg
(7, 14 days)
Inhalation
C57BL/6 mice Uniform particle uptake by
pulmonary macrophages. No
inﬂammatory or ﬁbrotic
changes were observed.
[35]
Silica NP 10-100g/mL (24 h,
48 h and 72 h)
A549 human
lung cancer
cells
Dose- and time-dependent
decrease in cell viability: up to
50% reduction at highest
dosage after 72 h. Oxidative
stress indicated as mechanism
of cytotoxicity.
[36]
Silica NP 5, 10, 20, 50 or
100g/mL (24 h)
Primary mouse
embryo
ﬁbroblasts
(BALB/3T3)
Dose-dependent reduction in
cell viability. Excessive ROS
generation and GSH depletion
suggest oxidative cell damage
as the underlying mechanism
of cytotoxicity.
[37]
Silica NP 25g/mL (24 h) A549 human
lung cancer
cells
HepG2 cells
RPMI 2650
human nasal
septal
epithelial cells
N2a mouse
neuroblast cells
Nuclear protein aggregation
and subsequent interference
with gene expression resulting
in inhibition of replication,
transcription and cell
proliferation.
[38]
Silica NP 0-185g/mL (24 h) A549 human
lung cancer
cells
EAHY926
endothelial
cells
J774 monocyte
macrophages
Dose-dependent increase in
cytotoxicity.
[39]
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Table 1 (Continued)
Target Nanoparticle Conjugation Concentration
(time/size)/route of
administration
Cellular target Animal target Major outcomes Ref.
Silica NP 33-47g/cm2 (small
NP), 89-254g/cm2
(larger NP) (24 h)
EAHY926
endothelial
cells
Size-dependent reduction in
viability with smaller particles
in the nanoscale exhibiting
higher toxicity compared to
particles >100 nm.
[40]
Silica NP 20mg/animal (1 or 2
months)
Intratracheal
instillation
Wistar rats Nano-sized silica particles
produced relatively lower
pulmonary ﬁbrosis compared to
micro-sized silica particles.
This is thought to be due to the
translocation of ultraﬁne
nanosilica away from the lung
parenchyma.
[41]
Silver NP 750g/m3 (4 h for 2
weeks)
Inhalation
Sprague-
Dawley
rats
No signiﬁcant changes in lung
function and body weight in
exposed groups compared to
fresh air controls.
[42]
Silver NP 61g/m3 (6 h/day, 5
days/week for 4
weeks)
Inhalation
Sprague-
Dawley
rats
No signiﬁcant clinical changes
or changes in haematology and
blood biochemical values.
[43]
Silver NP 515g/m3 (6 h/day, 5
days/week for 13
weeks)
Inhalation
Sprague-
Dawley
rats
Dose- and time-dependent
increase in blood Ag
nanoparticle concentration was
observed along with
correlating increases in
alveolar inﬂammation and
small granulomatous lesions.
[44]
Dermal Silver NP 50 and 100g/mL
(24 h)
NIH3T3 (mouse
ﬁbroblasts)
Mitochondria-dependent
cellular apoptosis associated
with ROS at a concentration of
≥50g/mL.
[45]
Silver NP 0.76-50g/mL (24 h) A431 (human
skin carcinoma)
No evidence for cellular
damage up to a concentration
of 6.25g/mL. Morphological
changes at concentrations
between 6.25 and 50g/mL
with concomitant rise in GSH,
SOD and lipid peroxidation.
DNA fragmentation suggests
cell death by apoptosis.
[46]
Toxicologicalconsiderations
of
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Table 1 (Continued)
Target Nanoparticle Conjugation Concentration
(time/size)/route of
administration
Cellular target Animal target Major outcomes Ref.
Silver NP 0-1.7g/mL (24 h) HEK cells Signiﬁcant dose-dependent
decrease in cell viability at a
critical concentration of
1.7g/mL with concomitant
rise in inﬂammatory cytokines
(IL-1, IL-6, IL-8, and TNF-).
[47]
0.34-34.0g/mL (14
consecutive days)
Porcine skin No gross irritations
macroscopically.
Ultrastructural observations
revealed areas of focal
inﬂammation and localization
of Ag NPs in stratum corneum
of the skin.
Silver NP Silver-coated wound
dressing ‘Acticoat’ (1
week)
Human burns
patient
Reversible hepatotoxicity and
argyria-like discoloration of
treated area of skin, elevated
plasma and urine silver
concentrations and increased
liver enzymes.
[48]
TiO2 NP 15g/cm2 (24 h) HaCaT
(keratinocyte
cell line),
human dermal
ﬁbroblasts,
human
immortalized
sebaceous
gland cell line
(SZ95)
Cytotoxicity was observed
affecting cellular functions
such as cell proliferation,
differentiation and mobility
resulting in apoptosis.
[49]
TiO2 NP 2mg/cm2 sunscreen
applied to volar
forearm 5× on days
1, 2 and 3; 1× on day
4 (tape stripping 1 h
post repetitive
application of
sunscreen)
Human
volunteers
Tape-stripping revealed no
nanoparticles in the deeper
layers of the stratum corneum.
Small amounts of NP (<1% of
total amount of sunscreen
applied) could only be
identiﬁed within pilosebaceous
oriﬁces.
[50]
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Table 1 (Continued)
Target Nanoparticle Conjugation Concentration
(time/size)/route of
administration
Cellular target Animal target Major outcomes Ref.
TiO2 NP NP containing
sunscreen
Human
volunteers
Increased skin permeation of
NP when sunscreen was
applied at hairy skin of human
volunteered.
[51]
TiO2 NP 2mg/cm2 sunscreen
applied to external
surface of upper arm
(tape stripping 5 h
post application of
sunscreen)
Human
volunteers
>90% of sunscreen recovered in
ﬁrst 15 tape strippings.
Remaining 10% did not
penetrate into viable tissue.
[52]
Silica NP 70, 300 and 1000 nm
in size
XS52 (murine
Langerhans
cells)
Size-related toxicity with
faster cellular uptake of
smaller particles and
concomitant higher toxicity.
[53]
Silica NP 30-300g/mL (48 h) CHK (human
keratinocytes)
Reduced cell viability. [54]
500g/mL (5 or 18 h) HSEM No irritation at 500g/mL.
500g/mL (24 and
72 h)
In vivo rabbit
model (Draize
skin irritation
test)
No erythema or oedema
formation observed - even on
tape-untreated animals.
Gold NP 95, 142 and
190g/mL (13 nm)
13, 20 and 26g/mL
(45 nm) (3 or 6 days)
CF-31 (human
dermal
ﬁbroblasts)
Cytotoxicity was size- and
dose-dependent. Larger
particles (45 nm) exhibited
greater toxicity at smaller
doses (10g/mL) compared to
smaller ones (13 nm) which
only exhibited cytotoxicity at a
concentration of 75g/mL.
[55]
Gold NP 0.8-15 nm in size
(48 h)
SK-Mel-28
(melanoma
cells), L929
mouse
ﬁbroblasts
Maximum cytotoxicity with
smaller NP (1.4 nm)
characterized by apoptosis and
necrosis.
[56]
Gold NP Citrate 0-0.8g/mL (14 nm in
size) (2, 4 or 6 days)
Human dermal
ﬁbroblasts
Dose-dependent reduction in
cell proliferation.
[57]
Toxicologicalconsiderations
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Table 1 (Continued)
Target Nanoparticle Conjugation Concentration
(time/size)/route of
administration
Cellular target Animal target Major outcomes Ref.
Gold NP 15, 102 and 198 nm in size Excised
abdominal skin
of Wistar rats
Size-dependent permeation through
rat skin with smallest NP having
deeper tissue penetration
[58]
Liver Gold NP Immunogenic
peptides:
• pFMDV
• pH5N1
8mg/kg/week (3-100 nm in
size) (4 weeks)
Intraperitoneal
BALB/C mice Naked NP: severe adverse effects
with resultant death with particles
ranging from 8 to 37 nm in diameter.
Microscopically, Kupffer cell
activation in the liver and lung
parenchymal destruction was
observed. Surface modiﬁed NP:
elicited increased host immune
response and improved
cytocompatibility.
[59]
Gold NP PEG 0.17, 0.85 and 4.26mg/kg
body weight (13 nm in size)
(30min after injection for 7
days)
Intravenous
BALB/C mice NPs were found to accumulate in
liver and spleen. Signiﬁcant
upregulation of inﬂammatory
cytokines (IL-1, 6, 10 and TNF-) with
subsequent apoptosis of hepatocytes
at highest concentrations
(4.26mg/kg). No signiﬁcant changes
in the liver at lower doses.
[60]
Gold NP PEG 4.26mg/kg (4 and 100 nm in
size) (30min)
Intravenous
BALB/C mice Both 4 and 100 nm sized gold NP
upregulated genes responsible for
inﬂammation, apoptosis and cell
cycle.
[61]
Gold NP 0.14-2.2mg/kg (13.5 nm in
size) (14-28 days)
Per oral, intraperitoneal or
intravenous
Highest toxicity was found with oral
and i.p. administration whereas
lowest toxicity was seen with tail
vein injection.
[62]
Silver NP 30 or 120g/mL dispersed
in ﬁsh tank (24 h)
Zebraﬁsh Oxidative stress-mediated toxicity
due to free Ag+ liberation. Induction
of pro-apoptotic signals in liver
tissues.
[63]
Silver NP 23.8, 26.4 or 27.6g/mL
single or repeated
administration (20, 80 and
110 nm, respectively), once
daily for 5 consecutive days
(1, 3, 5 days)
Intravenous
Wistar rats Size-related tissue uptake with
smaller NP (20 nm) showing higher
concentrations in organs than larger
ones. Accumulation of NP after
repeated administration has
implications for tissue toxicity.
[64]
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Table 1 (Continued)
Target Nanoparticle Conjugation Concentration
(time/size)/route of
administration
Cellular target Animal target Major outcomes Ref.
Silver NP 6.25-100g/mL for
primary ﬁbroblasts
and 12.5-200g/mL
for primary liver cells
(7-20 nm sized
spheres) (24 h)
Primary mouse
ﬁbroblasts,
primary
hepatocytes
NP enter cells which results in the
production of mediators of
oxidative-stress. However, protective
mechanisms could be observed which
increase GSH production to avoid
oxidative damage.
[65]
Silica NP 0.001g/mL (1, 3, 7,
15, and 30 days)
Intravenous
ICR mice Principle end-organs for NP
accumulation were liver, spleen and
lungs. Mononuclear cell inﬁltration at
hepatic portal area and hepatocyte
necrosis were observed.
[66]
Silica NP 50mg/kg (50, 100 or
200 nm in size) (12,
24, 48 and 72 h, 7
days)
Intravenous
BALB/C mice Size-dependent hepatic toxicity with
inﬂammatory cell inﬁltrates.
Macrophage-mediated frustrated
phagocytosis of larger NP (100 and
200 nm) resulted in release of
pro-inﬂammatory cytokines and cell
inﬁltrates within hepatic
parenchyma.
[67]
Silica NP PEG 2mg/kg (20-25 nm in
size) (24 h)
Intravenous
Nude mice Greatest accumulation of NP in liver,
spleen and intestines but no
pathological changes were observed
with small NP (<25 nm). Near-total
excretion of NP via the hepatobiliary
system.
[68]
Silica NP 10-100mg/kg (70,
300 or 1000 nm in
size)
Intravenous
BALB/C mice Signiﬁcant hepatotoxicity
(degenerative necrosis of
hepatocytes) was observed with
smaller NP (<100 nm) whereas no
pathological changes were seen with
larger particles (300 or 1000 nm),
even at relatively higher
concentrations of NP (100mg/kg).
[69]
CdSe QD ±ZnS shell 62.5, 250 and
1000g/mL (24 h)
Primary rat
hepatocytes
Cytotoxicity was thought to be due to
the release of free cadmium ions
which could not be fully eliminated
by ZnS coating of the OD core.
[70]
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Table 1 (Continued)
Target Nanoparticle Conjugation Concentration
(time/size)/route of
administration
Cellular target Animal target Major outcomes Ref.
CdSeTe OD ZnS shell
PEG
40 pmol (18.5 nm in
size) (1, 4 and 24 h;
3, 7, 14 and 28 days)
Intravenous
ICR mice Extravasation of small QD (<20 nm)
via hepatic capillary fenestrae
(∼100 nm) and deposition within liver
parenchyma.
[71]
CdSe QD ZnS shell 62.5, 100 and
250g/mL (24, 48 or
72 h)
HepG2 cells Dose-dependent cytotoxicity. In
extreme conditions (250g/mL for
72 h) a reduction in cell viability of
almost 40% was observed which
correlated with an increase in free
cadmium ion concentration of
1.51 ppm.
[72]
CdTe/CdSe QD ZnS
shell + either of
the following:
• organic
coating
• COOH
• NH2
• PEG
20, 40 or 80 nM (2, 4,
24 and 48 h)
J774.A1
(murine
‘macrophage-
like’
cells)
Regardless of coating, all QD induced
signiﬁcant cytotoxicity after 48 h as
measured by cell viability and LDH
release.
[73]
Brain Gold NP 0.8-50g/mL (3, 5,
7, 10, 30 and 60 nm)
(24 h)
rBMEC (primary
rat brain
microvessel
endothelial
cells)
No morphological changes could be
detected after 24 h suggesting
cytocompatibility of the NP tested.
Only the smallest NP tested (3 nm)
induced mild signs of cellular toxicity.
[74]
Gold NP (12.5 nm in size) (40,
200 or 400g/kg/day
for 8 days)
Intraperitoneal
C57/BL6 mice Small amounts of NP were able to
cross the BBB but did not induce
evident neurotoxicity.
[75]
Silver NP 6.25-50g/mL (25,
40 or 80 nm in size)
(24 h)
rBMEC (primary
rat brain
microvessel
endothelial
cells)
Time- and dose-dependent increase
in pro-inﬂammatory cytokine release
and correlating increases in
permeability and cytotoxicity of
cells.
[76]
Silver NP 10, 25 or 50g/mL
(1 h)
Wistar rat
tissue and
homogenates
In vitro activities of mitochondrial
respiratory chain complexes I, II, III,
and IV were decreased in the brain
and other tissues thus increasing the
potential for oxidative stress-induced
cell damage.
[77]
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Table 1 (Continued)
Target Nanoparticle Conjugation Concentration
(time/size)/route of
administration
Cellular target Animal target Major outcomes Ref.
Silver NP 30, 300 or
1000mg/kg/day for
28 days (60 nm in
size)
Per oral
Sprague-
Dawley
rats
Dose-dependent accumulation of NP
was observed in the brain and other
organs suggesting systemic
distribution after oral administration.
ALP and cholesterol increased
signiﬁcantly in high-dose group
(1000mg/kg/day) indicating
hepatotoxicity.
[78]
Silver NP 0.03, 0.1 or 0.3M
(4 h pf-5 days pf)
Zebraﬁsh
embryos
Neurobehavioural abnormalities were
observed in adult zebraﬁsh with
increased DA and 5HT turnover in
previously exposed embryos
secondary to altered synaptic
functioning.
[79]
(U)SPION 208 or 1042g/mL of:
• Ferumoxtran-10
(20-50 nm)
• Ferumoxytol
(20-50 nm)
• Ferumoxide
(60-185 nm)
(3 months)
Intracerebral
inoculation or
Intra-arterial after
BBB disruption
Long Evans rats Direct inoculation of all 3 SPION
agents resulted in the uptake into the
CNS parenchyma. No pathological
changes were detected.
[80]
CdSe QD ZnS shell
Captopril (cap)
conjugation
0.68mg containing
50 nmol Cd (13.5 nm
in size) (6 h)
Intraperitoneal
ICR mice Relatively high amounts of Cd ions
found in brain tissue but no signs of
inﬂammation or parenchymal damage
were observed.
[81]
Key: 5-HT, serotonin; Ag/Ag+, silver/silver ion; ALP, alkaline phosphatase; BAL, broncho-alveolar lavage; BBB, blood-brain-barrier; CdSe(Te), cadmium selenide (telluride); CNS, central
nervous system; DA, dopamine; GSH, glutathione; i.p., intraperitoneal; LDH, lactate dehydrogenase; MMP, matrix metallo-proteinase; MWCNT, multi-walled carbon nanotube; NP, nanopar-
ticle; PEG, poly(ethylene glycol); pf, post-fertilization; PLGA; poly(lactic-co-glycolic acid); ROS, reactive oxygen species; SWCNT, single-walled carbon nanotube; (U)SPION, (ultra) small
iron oxide nanoparticle; and ZnS, zinc sulphide.
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Lung targets
The lung is an attractive target for drug delivery due to the
non-invasive nature of inhalation therapy, the lung’s large
surface area, localization/accumulation of drugs within the
pulmonary tissue and avoidance of ﬁrst-pass metabolism,
thus reducing systemic side effects [82,83]. Nanocarrier sys-
tems for pulmonary drug delivery have several advantages
which can be exploited for therapeutic reasons and, thus,
are intensively studied.
Polymeric nanoparticles
Polymeric NPs are biocompatible, surfacemodiﬁable and are
capable of sustained drug release. They show potential for
applications in the treatment of various pulmonary condi-
tions such as asthma, chronic obstructive pulmonary disease
(COPD), tuberculosis (TB) and lung cancer as well as extra-
pulmonary conditions such as diabetes [84—89]. Already,
there is a multitude of organic nano-polymers including col-
lagen, gelatin, chitosan, alginate and bovine serum albumin
(BSA). Furthermore, the last three decades has seen a rise
in the development of synthetic polymers such as the bio-
compatible and biodegradable poly(lactic-co-glycolic acid)
(PLGA) for use as drug carrier devices [90,91].
While such drug loaded nano-conﬁgurations demon-
strate promising alternatives to current cancer treatment,
cytotoxicity needs to be evaluated. PLGA NP successfully
improve therapeutic outcome and reduce adverse effects
via sustained and targeted drug delivery. Additionally, the
use of biological capping materials such as chitosan or BSA
t
i
i
wly useful nanoparticles [30].
urther reduce toxicity while their biocompatibility and
iodegradative capacity making them an intuitive choice for
anoparticulate surface modiﬁcation. Romero et al. demon-
trated a reduction in cytotoxicity of PLGA NPs stabilized
ith BSA compared to synthetic coating materials in cul-
ured lung cancer cells [90]. Albumin, the most abundant
erum protein, was found to be highly biocompatible mak-
ng it a useful stabilizer for drug delivery vehicles. Similarly,
hitosan-stabilization resulted in near-total cellular preser-
ation and improved pulmonary mucoadhesion in an in vivo
ung cancer model [31].
Biological capping materials reduce cytotoxicity by mim-
cking the physiological environment, thus ‘hiding’ from
he immune system. However, the possibility of enzymatic
egradation due to biophysical resemblance needs further
nvestigation.
arbon nanotubes (CNTs)
NTs are frequently used for in vivo inhalation models and
an be subdivided into SWCNTs and MWCNTs with the former
eing considered more cytotoxic. This difference in toxicity
as been attributed to the larger surface area of SWCNTs
ompared to the multi-layered alternative [92]. CNTs show
iomedical potential in areas such as drug delivery, photo-
ynamic therapy (PDT) and as tissue engineering scaffolds
93—95]. Previous studies have highlighted the toxic poten-
ial of both SWCNTs and MWCNTs; after murine intra-tracheal
nstillation of CNTs, pulmonary epitheloid granulomas and
nterstitial inﬂammation with subsequent ﬁbrotic changes
ere observed [10,11,96]. Cytotoxicity is thought to be
598 L. Yildirimer et al.
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ediated by the up-regulation of inﬂammatory cytokines
uch as TNF-. However, a recent study by Mutlu et al. postu-
ates that toxicity after murine intra-tracheal instillation of
WCNTs arises due to nanotubular aggregation rather than
he large aspect ratio of the individual nanotube [9]. This
as led to the development of several methods to achieve
mproved nanotube dispersion [8]. Exposure of animals to
WCNTs results in contradictory reports with some authors
ppending toxicities in the range of asbestos poisoning
hereas other studies found MWCNTs to be biocompati-
le and far from cytotoxic [35,96]. Such discrepancies may
e explained by subtle variations in nanotube composition
nd ways of administration (intratracheal instillation versus
hole-body inhalation) and warrants further investigation.
ilica (SiO2) nanoparticles
ilica NPs are already in wide-spread use in the non-medical
eld as additives to chemical polishing, cosmetics, varnishes
nd food stuffs [36,97]. Relatively recently, such particles
ave been introduced into the biomedical ﬁeld as biomark-
rs [98], cancer therapeutics [99] and drug delivery vehicles
100]. Silica NPs are considered ‘safe’ in moderate dosage
<20g/mL) as opposed to their crystalline pendants which
re classed as class 1 carcinogens [36,37,101]. However, at a
ose of 25g/mL silica NPs exhibited agglomerative poten-
ial in vitro and dose-dependent cytotoxicity at a critical
oncentration of 50g/mL as demonstrated on A549 cells
38,39]. Cell death was mediated by reactive oxygen species
ROS) induction and membrane lipid peroxidation. Apart
rom concentration dependence, silica NPs further exhib-
ted particle size-dependent cellular toxicity with smaller
iameters causing more harm than bigger ones as shown by
apierska et al. [40]. Paradoxical results have been obtained
n animal studies focusing on the exposure of lungs to
ilica NPs. Previous studies on the pulmonary toxicity after
ntra-tracheal exposure of silica NPs have revealed profound
e
o
t
rization potential of gold nanoparticles [120].
cute pulmonary inﬂammation and neutrophil inﬁltration of
ung tissue with the development of chronic granulomatous
hanges after 14 weeks in a dose-dependent manner [102].
owever, subsequent longer-term studies utilizing the same
Ps showed the induction of anti-inﬂammatory mediators
nd the reversibility of inﬂammatory and ﬁbrotic changes
o levels close to the control [103,104]. Fibrogenic media-
ors (IL-4, IL-10 and IL-13) were upregulated shortly after
xposure to silica NPs and contributed to ﬁbrotic changes
104]. These were counteracted by the overexpression of
atrix-metalloproteinases (MMP), particularly MMP-2 and
nterferon gamma (INF-). Further to the expression of anti-
brotic mediators, eventual recovery of lung tissue may be
ssociated with the time-dependent reduction of NP con-
entration in the alveoli. Some studies suspect diffusion and
ranslocation of NPs away from the lung tissue via the sys-
emic circulation and deposition in extra-pulmonary organs
41,105,106]. The above suggests that it is theoretically fea-
ible and within acceptable safety limits to use moderate
oses of silica NPs; however high-dose toxicity proﬁles war-
ant further investigations.
ilver nanoparticles
he most common route of pulmonary exposure to silver
Ps (AgNP) is via the occupational inhalation of airborne
articles during manufacturing [107]. Oberdorster et al.
ave shown in a rat model that inhaled NPs can translocate
rom their original site of deposition (e.g. lungs) to other
issues [105]. The current American Conference of Govern-
ental Industrial Hygienist’s (ACGIH) limit for silver dust
xposure is 100g/m3. In order to evaluate potentially
cute and delayed adverse pulmonary effects of AgNP, Sung
t al. have carried out a series of inhalation studies focusing
n the acute, subacute (28 days) and subchronic (90 days)
oxicity of AgNP in rats [42,43,108]. In the acute setting,
ats were exposed to different particle concentrations in a
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whole-body inhalation chamber for 4 consecutive hours and
were subsequently observed for a further 2 weeks. At the
highest concentration used (750g/m3; 7.5 times higher
than the limit), no signiﬁcant body weight changes or clinical
changes were observed. Furthermore, lung function tests
revealed no statistical differences between exposed and
control groups. Repeated administration of AgNP for 4 weeks
showed similar results. In contrast, subchronic inhalation
for 13 weeks at a maximum concentration of 515g/m3
(5 times the limit) revealed time- and dose-dependent
alveolar inﬂammatory and granulomatous changes as well
as decreased lung function [44]. Such results suggest that
while high-dose chronic exposure to AgNP has the potential
to cause harm, under current guidelines and limits such
excessive particle inhalation would seem unrealistic.
Dermal targets
The skin is the largest organ of the body and functions as
the ﬁrst-line barrier between the external environment and
the internal organs of the human body. Consequently, it is
exposed to a plethora of non-speciﬁc environmental assaults
within the air as well as to distinct and potentially toxic sub-
stances within creams, sprays or clothing. Topically applied
NPs can potentially penetrate the skin and access the sys-
temic circulation and exert adverse effects on a systemic
scale.
Silver nanoparticles
Ag is one of the most consistently studied NPs in terms
of toxicity. This arises from the fact that AgNP possess
proven anti-microbial effects which are currently used in
many products ranging from wound dressings to clothing.
However, the speciﬁcity of AgNP toxicity towards micro-
organisms must be elucidated in order to exclude potentially
adverse effects mediated by such particles on other exposed
cell types within the body. Ag ingestion and topical appli-
cation can induce the benign condition known as argyria,
a grey—blue discoloration of the skin and liver caused by
deposition of Ag particles in the basal laminae of such tissues
[109]. This has prompted a limitation on the recommended
daily dosage of Ag. Furthermore, numerous toxicity stud-
ies focusing on AgNP have been carried out on cell lines
including mouse ﬁbroblast, rat liver, human hepatocellular
carcinoma and human skin carcinoma cells [5,45,46,110].
All observed a rise in ROS and oxidative-stress mediated
cell death and apoptosis (concentrations between 2.5 and
200g/mL). The degree of toxicity was concentration-
dependent and varied with surface coatings. Samberg et al.
reported signiﬁcant toxicity of uncoated AgNP on human epi-
dermal keratinocytes in contrast to carbon-coated particles
[47]. The exact mechanism of AgNP toxicity is unknown but
ROS generation and oxidative stress are two likely routes.
Once excessive ROS production outstrips the anti-oxidative
capacity of the cell, oxidative stress is induced with subse-
quent production of inﬂammatory mediators, DNA damage
and apoptosis [111]. Dermal penetration studies are ideally
carried out on porcine skin due to its resemblance to that of
humans in terms of thickness and rate of absorption [112].
Samberg et al. demonstrated porcine dermal biocompatibil-
ity after daily topical application of AgNP-containing cream
[
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ver a period of 14 consecutive days (0.34—34g/mL). How-
ver, microscopically, dose-dependent oedema formation
nd hyperplasia were observed with particle deposition in
uperﬁcial layers of the stratum corneum only. Trop et al.
bserved reversible silver toxicity in a human burns patient
ho was treated with a AgNP-coated dressing [48]. These
esults suggest reversible toxicity of AgNP and a transient
iscoloration of exposed skin.
itanium dioxide (TiO2) nanoparticles
iO2 NPs have several properties which make them an
dvantageous ingredient for commercial sunscreens and cos-
etics. They exhibit UV-light blocking properties and confer
etter transparency and aesthetics to creams. In vitro
tudies demonstrated cell type-dependent TiO2 toxicity
ffecting cellular functions such as cell proliferation, dif-
erentiation, mobility and apoptosis [49,113]. Such adverse
ffects, however, could not be replicated in vivo. In order
o assess penetrative capacities, dermal inﬁltration studies
ave been carried out on human volunteers using differ-
nt investigative techniques. Lademan et al. investigated
he penetrative effect of repeated administration of TiO2-
ontaining sunscreen on the skin of volunteers [50]. Tape
tripping and histological appraisal of skin biopsies revealed
hat TiO2 penetrated into the open part of a hair follicle as
pposed to the viable layers of the epidermis or dermis. Fur-
hermore, the titanium amount in any given follicle was less
han 1% of the applied total amount of sunscreen. Surface
enetration via hair follicles or pores was also suggested
y a study conducted by Bennat and Muller-Goymann where
kin permeation was greater when sunscreen was applied to
elatively hairy skins [51]. Mavon et al. demonstrated near
otal recovery of sunscreen after 15 tape strippings with no
iO2 deposition in hair follicles or skin layers [52]. It could
e argued that different degrees of permeation and toxic-
ty correlate with surface coatings and functionalizations of
iO2 NPs as well as with the number of follicular pores within
he skin facilitating particle uptake.
ilica nanoparticles
ilica NPs are frequently incorporated in drug additives
nd cosmetics as well as being used as nano-vehicles for
rug delivery [114,115]. However, sparse literature on its
utaneous toxicity is available. Cell-based toxicity studies
evealed a size-related increase in cytotoxicity when murine
pidermal Langerhans cells were exposed to silica particles
f diameters 70, 300 and 1000 nm [53]. Cellular uptake was
ore efﬁcient for smaller particles (<100 nm) which corre-
ated with an increased cytotoxicity. Park et al. evaluated
oxicity of differently sized silica NPs on cultured human ker-
tinocytes (CHK) and compared results with a human skin
quivalent model (HSEM) as well as with an in vivo rabbit
odel [54]. Silica NPs exhibited signiﬁcant dose-dependent
oxicity on human keratinocytes with a statistically
igniﬁcant reduction in cell viability at a concentration of
0g/mL. A size-dependent increase in toxicity, as sug-
ested by Jiang et al. could, however, not be conﬁrmed
116]. Exposure of NPs to HSEM showed no inﬂammatory
hanges even at a maximum concentration of 500g/mL.
uch low acute toxicity was conﬁrmed with the in vivo rabbit
kin model. These results highlight the superiority of HSEM
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ompared to culture-based systems in terms of evaluating
elative dermal toxicities of NPs and emphasize the discrep-
ncies encountered if one tries to extrapolate results gained
rom cell-based studies into human scenarios.
old nanoparticles
ue to facile means of synthesis and the potential for bio-
unctionalization, gold NPs (AuNP) are being investigated for
linical applications including dermal drug-delivery [117].
onavane et al. demonstrated size-dependent permeation
n excised rat skin after topical application of differently
ized AuNP (15, 102 and 198 nm) [58]. Smaller NPs pene-
rated deeper into the tissue than larger ones which were
ainly accumulated in the more superﬁcial epidermis and
ermis. These ﬁndings may have important implications with
egards to efﬁcient NP-based dermal drug delivery. Au com-
ounds are generally considered safe and have been in
outine clinical use for many years, e.g. in the treatment
f rheumatoid arthritis [118]. However, once reduced to
anometer scale, particles are known to undergo profound
hanges in terms of their biochemical properties which
ecessitates renewed investigations into their cytotoxic pro-
le. Despite the relative wealth of toxicity studies focusing
n AuNP, contradictory results remain the main obstacle
o transition into the clinical setting. Several studies have
emonstrated cellular uptake of AuNP to be a function of
ime, particle size and concentration. In a study by Miron-
va et al., human dermal ﬁbroblasts were exposed to AuNP
or a period of up to 6 days [55]. Three sets of NP concentra-
ions were obtained for each of two different sizes. Larger
articles, 45 nm, exhibited marked cytotoxicity at a concen-
ration of 10g/mL compared to smaller particles, 13 nm
n size, which only displayed cytotoxic signs at the much
igher concentration of 75g/mL. These results conﬂict
ith those obtained by Pan et al. who reported maximum
oxicity for a particle size of 1.4 nm [56]. Such differences
ay be explained by the distribution pattern of particles
ithin cells and require more research.
iver targets
eing the site for ﬁrst-pass metabolism, the liver is partic-
larly vulnerable to NP toxicity and has consistently been
hown to accumulate administered substances, even long
fter cessation of exposure. Thorough evaluation of NP-
ediated hepatocellular toxicity thus remains of prevailing
mportance.
old nanoparticles
uNP play an interesting role in biomedicine and have mul-
iple possible applications in the ﬁelds of imaging, drug and
ene delivery [14,119]. A study conducted by Chen et al.
evealed size-associated toxicity and lethality of AuNP [59].
ice were exposed to intraperitoneal injection with naked
uNP ranging from 3 to 100 nm in size at a concentration
f 8mg/kg/week for 4 weeks. Particles sized 3, 5, 50 and
00 nm did not induce signiﬁcant toxicity. However, particles
anging from 8 to 37 nm induced severe systemic adverse
ide effects in the test subjects such as fatigue, loss of
ppetite, weight loss and fur color changes. Death rates
f mice exposed to that particular size range were near
p
h
s
mL. Yildirimer et al.
otal. Histological examination of organs indicated Kupf-
er cell activation in the liver, splenic white pulp diffusion
nd structural deformities in lung parenchyma which were
onsistently associated with gold deposition at these sites.
oxicity was improved by surface modiﬁcation of parti-
les with a highly immunogenic peptide which induced an
ncreased antibody response in the host. Despite improved
ytocompatibility conferred by biological surface coatings,
he primary mechanism of liver toxicity is thought to arise
rom acute inﬂammatory changes and subsequent apopto-
is [60,61]. Increasingly, evidence shows that AuNP toxicity
epends not only on the conventionally listed properties
ncluding surface functionalization but also on the route of
dministration [62,120]. It has been shown that intraperi-
oneal administration of particles is related to a signiﬁcantly
igher incidence of adverse effects than comparable intra-
enously delivered ones [62]. Despite the fact that these
ndings may have implications for clinical uses of such par-
icles, caution should be exercised when stating that one
oute of administration gives a higher incidence of adverse
ffects than another, especially when based on toxicity
esults from different studies.
ilver nanoparticles
ell known for their anti-microbial effects, AgNP may gain
ccess into the circulation via various routes. Once within
he systemic circulation, ﬁrst-pass metabolism via the liver
s likely, if not probable, thus potentially rendering hep-
tocytes vulnerable to toxic insults. Many studies have
ndicated the propensity for AgNP to accumulate within the
iver and induce oxidative stress-related toxicity [63]. Cer-
ain parameters inﬂuencing the degree of toxicity include
article concentration [121], size [64], shape [65] and the
bility to deplete cells of anti-oxidants [122]. Teodoro
t al. demonstrated signiﬁcant toxicity exerted by AgNP on
RL3A rat liver cells by measuring a signiﬁcant reduction in
itochondrial function, a concomitant rise in lactate dehy-
rogenase (LDH) leakage from cells, signiﬁcantly depleted
evels of the antioxidant glutathione (GSH) as well as a rise in
OS concentrations [122]. Oxidative stress-dependent cyto-
oxicity was also conﬁrmed by Kim et al. who were able to
igniﬁcantly improve viability of rat hepatoma cells exposed
o AgNP after pre-treating cells with the naturally occurring
nti-oxidant N-acetylcysteine [121].
ilica nanoparticles
iomedical applications for silica NPs are widespread and
nclude diagnosis and drug delivery [123,124]. Despite such
romising uses in the medical arena, a thorough evaluation
f cytotoxicity is still lacking. Few studies have been car-
ied out and contradictory results regarding toxicity further
ecessitate systematic research. Xie et al. demonstrated
he hepatotoxic potential of silica NPs causing mononu-
lear inﬂammatory cell inﬁltrates at the portal area with
oncomitant hepatocyte necrosis [66]. Such inﬂammatory
hanges are postulated to relate to frustrated phagocytosis
f larger silica NPs (>100 nm) with subsequent stimulation of
ro-inﬂammatory cytokine release [67]. A size relationship
as also been reported by Kumar et al. who found small
ilica NPs (<25 nm) to be biocompatible and non-toxic to
urine liver parenchyma [68]. In contrast to these ﬁndings,
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Nishimori et al. suggests acute toxicity related to small sil-
ica NPs (<100 nm) [69]. Several factors may lead to these
apparently inconsistent results; the presence or absence
and type of coating is one of the major parameters in
determining interactions between the NPs and physiological
environment as is the particle’s size. However, contradic-
tory results in terms of size-dependent toxicity warrant
further investigations into the role of different routes of
particle administration. The results for silica NPs suggest
that less invasive means of administration (e.g. oral) reduce
organ-speciﬁc toxicity compared to intravenously dispensed
particles. Building on this theory, intravenously given larger
NPs (>100 nm) may prove less cytotoxic due to impaired
extravasation through minute capillary fenestrae and thus,
little organ-speciﬁc deposition, as postulated by Nishimori
et al. [69].
Quantum dots
Semiconductor nanocrystals, or QDs may be used in a
variety of biomedical applications. The general structure
of QDs comprises an inorganic core—shell and an organic
coating to which biomolecules may be conjugated to enable
targeting to speciﬁc areas within the body. Such close prox-
imity and interaction with the physiological environment
necessitates toxicological evaluation of these particles. Cell
based studies focusing on QD-induced adverse effects found
toxicity most likely arises from the liberation of metal
ions released from the heavy metal core [70]. Oxidative
environments further promote degradation and metal ion
leaching. The liver is of particular importance with regards
to bio-toxicity because of ﬁrst-pass metabolism and poten-
tial accumulation and deposition within the organ, as shown
by Yang et al. [125]. QD size was also postulated to be a
major parameter in organ-speciﬁc deposition with smaller
particles (<20 nm) extravasating through capillary fenestrae
that are large enough in the liver (∼100 nm in size) [71].
The long half-life clearly has implications for organ toxicity,
particularly in view of the liver’s untoward propensity to
heavy metal ion poisoning which makes exposure to QDs
potentially very hazardous. Surface coating to protect the
core from degradation has been shown to reduce toxicity
[126]. Conventionally, QDs are coated with a layer of zinc
sulphide (ZnS) or mercaptoacetic acid. However, evidence
of continued cellular toxicity after prolonged periods of
time suggests either inadequate core coverage or the need
for a different type of coating material [72]. Clift et al.
carried out a series of experiments assessing additional
surface coatings for their respective cytotoxicities [73].
CdTe/CdSe cored QDs with a ZnS shell were additionally
covered with organic, carboxylated (COOH), amino (NH2)
or poly(ethylene glycol) (PEG) coatings. Cytotoxicity was
tested on exposure to each type separately by measurement
of macrophage cell viability and LDH release. All QDs were
shown to induce signiﬁcant cytotoxicity after 48 h and coat-
ing materials as well as liberated Cd ions were suggested
to be the causative agents. It is likely that a breakdown of
physically labile surface material resulted in ion liberation
and subsequent toxicity. Recently, Seifalian and colleagues
have demonstrated that the novel synthetic nanomaterial
polymeric oligohedral silsesquioxane (POSS), when incor-
porated onto CdTe cored QDs, shows signiﬁcantly enhanced
d
c
s
As 601
ytocompatibility than conventionally used materials, even
ithout ZnS shelling (unpublished data). POSS was shown to
e non-toxic by preventing ion leakage from the core. These
esults underline the importance of the type of coating
aterial used and suggest that the most important factor
nﬂuencing QD toxicity remains heavy metal ion leakage
rom the core due to inadequate surface coverage.
rain targets
he brain, unlike the liver, has very limited regenerative
apacity and must therefore be particularly protected from
xogenous insults. This is achieved by the protective BBB
hich separates the cerebrospinal ﬂuid (CSF) surrounding
he brain from the systemic blood circulation via tight junc-
ions around the capillaries and is of undoubted beneﬁt
n preventing blood-borne pathogens from gaining entry
nd causing potentially irreversible damage while allowing
he diffusion of smaller lipophilic molecules such as oxy-
en. However, bypassing the BBB may be beneﬁcial and
otentially life-saving in the management of acute condi-
ions such as cerebral meningitis as well as chronic illnesses
ike dementia or Parkinson’s disease. Targeted drug delivery
llows the use of smaller drug doses and hence reduces sys-
emic adverse effects. Nevertheless, the fate of NPs after
ranslocation into the structures of the central nervous sys-
em (CNS) requires toxicological analyses. External insult to
he BBB could potentially activate cerebral epithelial cells
hus inducing oxidative stress-mediated injury. Additionally,
he integrity and biostability of the particle’s coating mate-
ials require rigorous assessment [127].
Recently, Oberdorster et al. demonstrated the uptake of
Ps by sensory nerve endings within the pulmonary epithe-
ium and subsequent axonal translocation into the CNS which
resents a further route of exposure to potentially harmful
Ps [127].
old nanoparticles
uNP are valuable imaging modalities for in vitro and
n vivo cell tracking. Studies suggesting AuNP as imaging
gents of the CNS are manifold and could prove to be use-
ul in the diagnoses and therapeutics of CNS pathologies
128—130]. However, such enthusiasm is dampened by the
elative paucity of data on the interactive capabilities of
uNP with the cells of the CNS. Primary brain microvascu-
ar endothelial cells (BMECs) are frequently used to provide
nformation on BBB transport characteristics and molec-
lar mechanisms and offer an opportunity to investigate
nto the interactions between NPs and the surface of the
BB [131—133]. It has been postulated that the release
f pro-inﬂammatory cytokines (e.g. TNF-, IL- and IL-
) induces an increase in permeability and toxicity in rat
rain microvessel endothelial cells (BMECs) exposed to
gNP which seemed both size- and time-dependent [76].
n contrast, a similar study utilizing AuNP of comparable
imensions did not evoke increased secretion of inﬂam-
atory markers nor was enhanced cellular permeability
etectable [74]. These ﬁndings are supported by a study
arried out on RAW264.7 macrophage cells which demon-
trated no pro-inﬂammatory cytokine release in response to
uNP exposure [75]. However, mild toxicity was observed
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ith smaller AuNP (3 nm) compared to larger ones (5 nm).
uch size-dependent toxicity has previously been observed
n various cell lines [134,135] and in vivo models [136,137].
ltra-small NPs were found to be widely distributed to
lmost all tissues including the brain whereas larger ones
ere barred access to cerebral tissues. This could be due
o either the physical hindrance provided by the BBB or the
aster and more efﬁcient removal of larger particles from
he circulation compared with smaller ones. Consequently, a
ower particle concentration would reach and subsequently
e absorbed by the BBB. The BBB’s regulatory function as
ell as the removal-theory were further demonstrated in
different study where, even after repeated administra-
ion of relatively large AuNP (12.5 nm), the amount in the
rain was signiﬁcantly lower than that in the liver, spleen
nd kidneys [138].
ilver nanoparticles
n contrast to Au, AgNP have been shown to exhibit neu-
odegenerative abilities [139,140]. Recent research focusing
n the interaction between AgNP and BBB has revealed
unctional disruption of the BBB and subsequent brain
edema formation [139]. In support of these ﬁndings, Tang
t al. demonstrated AgNP-induced BBB destruction, astro-
yte swelling and neuronal degeneration in a rat model
140,141]. The pattern of distribution and degree of toxic-
ty was found to be concentration- and size-dependent [64].
study conducted by Costa et al. suggests mitochondrial
ysfunction and impaired energy production as the possible
nderlying mechanism of neurodegeneration [77]. Repeated
dministration resulted in signiﬁcant accumulation in organs
ith smaller AgNP (<100 nm) being predominantly picked up
y the liver while larger particles (>100 nm) mainly accu-
ulated in the spleen. This pattern of particle uptake is
egulated by the pore size of capillary fenestrae (∼100 nm).
ose-dependent accumulation has previously been observed
n rats following repeated oral doses of AgNP [78]. Human
ubjects demonstrated a greyish hyperpigmentation of their
kin following oral ingestion of AgNP [142,143]. These results
uggest the capacity for gastrointestinal absorption of AgNP
ith subsequent systemic distribution and accumulation in
arious tissues.
This apparent potential for AgNP to accumulate and
ause harm requires further investigation with particular
ttention assigned to the inﬂuence of NP size on the
istribution and toxicity. Powers et al. demonstrated the
otential for AgNP to behave as a developmental neurotoxin
n zebraﬁsh embryos and cause long-term changes in synap-
ic functioning [79]. Exposure to ionized silver (Ag+)
esulted in a marked increase in turnover of the neuro-
ransmitters dopamine (DA) and serotonin (5-HT) which are
ey components in the reward, anxiety and sensorimotor
athways. Ag+-induced neurotransmitter hyperactivity
esulted in behavioural changes consistent with a lower
nxiety-threshold.
uperparamagnetic nanoparticles
PIONs and ultra-small SPIO nanoparticles (USPIONs) consist
f an iron oxide core and a variable carbohydrate coating
hich determines cellular uptake and biological half life.
he degree of surface coverage has been postulated to be
Q
a
e
pL. Yildirimer et al.
he main parameter in cellular uptake as incomplete sur-
ace coverage was shown to promote opsonization and rapid
ndocytosis whereas fully coated SPION escaped opsoniza-
ion which, as a result, prolonged plasma half-life [144].
owever, more recently, particle size as opposed to coat-
ng degree has been suggested to exert chief inﬂuence on
he rates of uptake by macrophages [145]. Being one of
he few FDA approved NPs for the use in MRI, SPION most
ommonly ﬁnd applications in the imaging of the vascula-
ure and lymph nodes [146—149]. However, recent reports
rom both animal models and human subjects have shown
heir efﬁcacy in visualizing intracerebral malignancies and
eurological lesions within the CNS [150,151]. Despite such
outine use of SPION, the long-term effects and potential
eurotoxicity have, as yet, not been evaluated extensively.
The unique physio-chemical properties shared by all NPs,
uch as nanometer size and a large surface area to volume
atio, makes SPION particularly valuable for novel therapeu-
ic and diagnostic applications. However, such dimensional
eductions may potentially induce cytotoxicity and inter-
ere with the normal components and functions of the cell
152,153]. Previous in vitro studies have shown the capac-
ty for SPION to induce ROS generation, impair mitochondrial
unction and cause leakage of LDH — all of which could incite
eurotoxicity as well as potentially aggravate pre-existing
euronal damage [154—156]. Furthermore, toxicity reports
emonstrated an association between particle size, type
f surface coating and breakdown products, concentration
nd the degree of opsonization and cytotoxicity in cultured
ells [157—159]. For example, Berry et al. utilized ﬁbro-
last cultures to demonstrate the ability to tune particle
oxicity according to particle coating. They compared the
n vitro toxicity of plain, uncoated magnetic iron oxide NPs
P particles) with either dextran derivatized (DD) or albu-
in derivatized (AD) NPs. P particles as well as DD particles
xhibited similar toxicities, whereas AD particles managed
o induce cell proliferation [157].
In a study by Muldoon et al., the distribution, cellular
ptake and toxicity of three FDA approved SPION of dif-
erent sizes and surface coatings were compared to each
ther and to a laboratory reagent [80]. Firstly, inoculation
f ferumoxtran-10 (USPION: 20—50 nm in size, complete sur-
ace coverage with native dextran), ferumoxytol (USPION:
0—50 nm in size, complete surface coverage with semisyn-
hetic carbohydrate) and ferumoxide (SPION: 60—185 nm
n size, incompletely coated with dextran) as well as
he lab reagent MION-46 into tumor-bearing rat brains
emonstrated direct uptake of ferumoxtran-10 into tumor
issue and long-term retention within the cancerous lesion
5 days). However, uptake seemed NP dependent. Feru-
oxide inoculation did not yield tumor enhancement which
uggests size and surface coverage dependence. The sec-
nd step involving osmotic BBB disruption to evaluate
ransvascular SPION delivery and neurotoxicity displayed
o evidence of gross pathology implying the feasibility of
ntracerebral injection of clinical USPION into humans.
uantum dots
Ds may be functionalized to serve both diagnostic
nd therapeutic purposes. Presently, QDs ﬁnd invaluable
xperimental applications in visualizing neural stem and
rogenitor cells in developing mouse embryos in vivo [160],
ticle
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RToxicological considerations of clinically applicable nanopar
act as nano-vehicles for brain-targeted drug delivery [161]
and demarcate brain malignancies for precise tumor resec-
tion [162]. Previously, it has been suggested that NPs can
bypass the BBB and reach the brain via the olfactory epithe-
lium or trigeminal nerve to potentially cause harm [163].
In order to investigate the potential to reach the structures
of the CNS, Kato et al. intraperitoneally injected CdSe/ZnS-
core/shell-typed QDs functionalized with captopril with a
diameter of 13.5 nm into mice [81]. Six hours post-injection,
organs were harvested and brains were dissected into sev-
eral areas including the olfactory bulb, cerebral cortex,
hippocampus, thalamus and brainstem. Despite the detec-
tion of unexpectedly high amounts of Cd within the brain
tissues, no signs of inﬂammation, neuronal loss or functional
disorders were present. Several possible routes of entry
into the brain have been suggested. Small QDs may transfer
through minute gaps (<20 nm) between astrocytic foot pro-
cesses which constitute the BBB out of the capillary bed into
the brain parenchyma. Alternatively, interaction between
QD-cap and the receptors located at the BBB may lead to the
uptake of QDs via phagocytosis or pinocytosis [164]. How-
ever, no evidence for the presence of captopril receptors
at the BBB has been published making receptor-mediated
uptake unlikely. Another postulated route of entry into the
brain is the retrograde axonal transport from gut neurones
via peripheral nerves into the tissues of the CNS. However,
according to the published report, no QD-cap was found in
peripheral nerves. These results suggest that for clinical or
therapeutic purposes, the route across the BBB may show
promise in the future management of CNS pathologies. How-
ever, the combination of scarce clinical data on the toxic
effects with the lack of long-term in vivo toxicity studies
calls for the need for considerable attention to the system-
atic evaluation of QDs intended for brain-speciﬁc purposes.
Conclusion
NPs have certain unique characteristics which can be and
have been exploited in many biomedical applications. How-
ever, these unique features are postulated to be the grounds
for NP-induced biotoxicity which arises from the complex
interplay between particle characteristics (e.g. size, shape,
surface chemistry and charge), administered dose and host
immunological integrity. Recently, more emphasis has been
placed onto understanding the role of the route of particle
administration as a potential source for toxicity. Current
research focuses on elucidating the mechanistics underlying
NP toxicity which are postulated to range from inﬂammatory
cell inﬁltration and cellular necrosis to ROS-induced apo-
ptosis. Despite the wealth of toxicity studies available, the
authors have identiﬁed several points of criticism which cur-
rently hinder the progression into clinical settings. Firstly,
the application of the so-called ‘proof of principle’ approach
where cell cultures or experimental animals are exposed to
ultra-high NP concentrations to ensure cytotoxicity leads to
unrealistic results which cannot be extrapolated into the
human scenario since diagnostic and therapeutic interven-
tions usually only require the administration of minimal
concentrations. Thus, not only are we faced with scientiﬁ-
cally unreliable data, such practices may, quite dangerously
cause unnecessary alarm in the public. Additionally, the
authors have identiﬁed two further limitations of currents 603
oxicity studies; ﬁrstly, the chronicity of NPs exposure in the
ase of therapeutic applications needs more thorough long-
erm evaluation; secondly, different studies apply different
article formulations leading to conﬂicting and unreliable
esults. Consequently and for the future, more emphasis
hould be placed on deﬁning the dose of NPs in relation
o the route of administration. As mentioned at the begin-
ing, end-organ accumulation and distribution as well as
etabolism and excretion are variable depending on the
outes of administration, such that intravenous NP adminis-
ration may have more implications with regards to systemic
dverse effects than dermal application of NPs. However,
ne must treat and compare toxicity results from differ-
nt studies with caution, as current toxicity protocols lack
niformity with respect to NP formulations and application
rotocols. It has become apparent that a unifying protocol
or the toxicological proﬁling of NPs may be required in order
o achieve reliable outcomes that have realistic implications
or the human usage of NPs. In summary, current difﬁculties
n evaluating NP toxicity originate in the inherent discrepan-
ies found amongst toxicity study protocols such that is has
ecome apparent that a unifying protocol for the toxico-
ogical proﬁling of NPs may be required in order to achieve
eliable outcomes that have realistic implications for the
uman usage of NPs. Not only is there a pressing need for
ong-term studies, the future of nanotoxicology must also
ore heavily rely on realistic particle dosages and compo-
ition principles as well as differentiating more carefully
etween various routes of administrations if nanotechnology
s to fully unfold its clinical potential.
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